CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 307 enrolled
Drug / intervention
adalimumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01468207
NCT01468207Phase 3Completed
CompareCT.gov

A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER I

AbbVie (prior sponsor, Abbott)·interventional·Posted Nov 9, 2011·Updated Jul 7, 2021

In Brief

A Phase 3 clinical trial evaluating adalimumab and placebo for Hidradenitis Suppurativa (HS). Completed, enrolled 307 participants.

Detailed Summary

A study to evaluate the safety and efficacy of treatment with adalimumab in adults with moderate to severe hidradenitis suppurativa (HS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHidradenitis Suppurativa (HS)
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 9, 2011
Enrollment StartNov 1, 2011
Primary CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 14.6 years ago

Interventions

adalimumabbiological

Adalimumab pre-filled syringe, administered by subcutaneous injection

placebobiological

Placebo pre-filled syringe, administered by subcutaneous injection